Nirubol Tosakulwong

Nirubol Tosakulwong

Auto-generated profile, based on publicly available information

Nirubol Tosakulwong

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in NeuroImage: Clinical
Verified
Journal Article
Open access
HBHugo Botha
Hugo Botha
RURene L. Utianski
Rene L. Utianski
JWJennifer L. Whitwell
Jennifer L. Whitwell
JDJoseph R. Duffy
Joseph R. Duffy
HCHeather Clark
Heather Clark
DJDavid T. Jones
David T. Jones
Apraxia of speech is a motor speech disorder thought to result from impaired planning or programming of articulatory movements. It can be the initial or only manifestation of a degenerative disease, termed primary progressive apraxia of speech (PPAOS). The aim of this study was to use task-free functional magnetic resonance imaging (fMRI) to assess large-scale brain network pathophysiology in PPAOS. Twenty-two PPAOS participants were identified from a prospective cohort of degenerative speech and language disorders patients. All participants had a comprehensive, standardized evaluation including an evaluation by a speech-language pathologist, examination by a behavioral neurologist and a multimodal imaging protocol which included a task-free fMRI sequence. PPAOS participants were age and sex matched to amyloid-negative, cognitively normal participants with a 1:2 ratio. We chose a set of hypothesis driven, predefined intrinsic connectivity networks (ICNs) from a large, out of sample independent component analysis and then used them to initialize a spatiotemporal dual regression to estimate participant level connectivity within these ICNs. Specifically, we evaluated connectivity within the speech and language, face and hand sensorimotor, left working memory, salience, superior parietal, supramarginal, insular and deep gray ICNs in a multivariate manner. The spatial maps for each ICN were then compared between PPAOS and control participants. We used clinical measures of apraxia of speech severity to assess for clinical-connectivity correlations for regions found to differ between PPAOS and control participants. Compared to controls, PPAOS participants had reduced connectivity of the right supplementary motor area and left posterior temporal gyrus to the rest of the speech and language ICN. The connectivity of the right supplementary motor area correlated negatively with an articulatory error score. PPAOS participants also had reduced connectivity of the left supplementary motor area to the face sensorimotor ICN, between the left lateral prefrontal cortex and the salience ICN and between the left temporal-occipital junction and the left working memory ICN. The latter connectivity correlated with the apraxia of speech severity rating scale, although the finding did not survive correction for multiple comparisons. Increased connectivity was noted in PPAOS participants between the dorsal posterior cingulate and the left working memory ICN. Our results support the importance of the supplementary motor area in the pathophysiology of PPAOS, which appears to be disconnected from speech and language regions. Supplementary motor area connectivity may serve as a biomarker of degenerative apraxia of speech severity.

24 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
KJKeith A. Josephs
Keith A. Josephs
NTNirubol Tosakulwong
Nirubol Tosakulwong
SWStephen D. Weigand
Stephen D. Weigand
JGJonathan Graff-Radford
Jonathan Graff-Radford
CSChristopher G. Schwarz
Christopher G. Schwarz
JWJennifer L. Whitwell
Jennifer L. Whitwell
[ 18 F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of Alzheimer’s disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by amyloid-β. It is also unclear whether flortaucipir can detect tau in definite primary age–related tauopathy (PART). We identified 248 individuals at Mayo Clinic who had undergone [ 18 F]-flortaucipir PET during life, had died, and had undergone an autopsy, 239 cases of which also had amyloid-β PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage, and Thal amyloid-β phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with a high amyloid-β phase. Flortaucipir uptake linearly increased with the amyloid-β phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer’s disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with the entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART, and imaging-defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored the histopathological tau distribution, were influenced by the amyloid-β phase, and were useful for distinguishing different ADNC scores and PART.

4 February 2022 in NeuroImage: Clinical
Verified
Journal Article
Open access
MBMarina Buciuc
Marina Buciuc
PMPeter R. Martin
Peter R. Martin
NTNirubol Tosakulwong
Nirubol Tosakulwong
MMMelissa E. Murray
Melissa E. Murray
LPLeonard Petrucelli
Leonard Petrucelli
KJKeith A. Josephs
Keith A. Josephs
• Rates of anterolateral temporal lobe atrophy are faster in FTLD-TDP versus AD-TDP. • Older age is associated with slower frontal lobe atrophy in FTLD-TDP. • AD-TDP type-α showed faster medial temporal atrophy than type-β. • Pure-TDP was associated with slowest rates and less atrophy in all brain regions.

17 August 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
NBNegin Badihian
Negin Badihian
NTNirubol Tosakulwong
Nirubol Tosakulwong
SWStephen D. Weigand
Stephen D. Weigand
FAFarwa Ali
Farwa Ali
HCHeather M. Clark
Heather M. Clark
KJKeith A. Josephs
Keith A. Josephs

22 July 2025 in Menopause
Verified
Journal Article
Open access
LFLaura L. Faubion
Laura L. Faubion
EMElijah Mak
Elijah Mak
FKFirat Kara
Firat Kara
NTNirobul Bs Tosakulwong
Nirobul Bs Tosakulwong
TLTimothy G. Lesnick
Timothy G. Lesnick
KKKejal Kantarci
Kejal Kantarci
Objectives: To assess the long-term effects of 4 years of menopausal hormone therapy (mHT) on the brain’s white matter architecture in women who initiated mHT within 3 years of menopause onset. Methods: The Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, double-blind, randomized, placebo-controlled 4-year mHT trial with treatment arms of oral conjugated equine estrogens (oCEE), transdermal 17β-estradiol (tE2), and placebo in recently postmenopausal women. KEEPS Continuation was an observational follow-up of KEEPS participants. White matter integrity was evaluated in KEEPS Continuation participants 10 years after KEEPS completion using white matter hyperintensity volume, diffusion magnetic resonance imaging (dMRI) techniques, and cerebral infarcts. Linear regression models were fitted for each brain region to evaluate if there were differences in white matter between KEEPS treatment arms. Results: There was no evidence to suggest the long-term effects of 4 years of mHT on brain white matter in KEEPS Continuation participants [n=266, mean age 67 (58-73)]. No differences in dMRI metrics were found in each of the treatment arms (oCEE n=70; tE2 n=79) when compared to placebo (n=94), following a false discovery rate adjustment for multiple comparisons. There were no statistically significant differences in white matter hyperintensity volume or infarct occurrence when comparing each of the treatment arms to placebo. Conclusions: We found no evidence of the long-term effect of 4-year mHT on white matter integrity when compared to placebo, consistent with emerging evidence of the safety of short-term use of mHT in recently postmenopausal women.

20 October 2023 in Medicine
Verified
Journal Article
Open access
JBJoana Bs Beyer
Joana Bs Beyer
RCRonan Bs Couch
Ronan Bs Couch
KRKathryn J. Ruddy
Kathryn J. Ruddy
BZBurcu Zeydan
Burcu Zeydan
NTNirubol Bs Tosakulwong
Nirubol Bs Tosakulwong
FKFirat Kara
Firat Kara
Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We analyzed 11 women with newly diagnosed stage 1 to 3 breast cancer. Patients were evaluated via objective cognitive testing, and patient self-report tests. Patients were examined using single voxel proton magnetic resonance spectroscopy in the medial frontal cortex, posterior cingulate gyrus, and left thalamus at baseline and after the completion of chemotherapy on a 1.5 Tesla scanner. At the posttreatment evaluation as compared to baseline, 7 of the 10 (70%) patients reported worsening memory on the MD Anderson symptom inventory (annualized change = 1.82 ± 2.88, P = .08), while the delayed recall raw score of the Rey Osterrieth complex figure test did not change from pre- to post-chemotherapy (mean annualized change = 5.00 ± 14.38, P = .30). The annualized change in the creatine concentration in the posterior cingulate gyrus was statistically significant. The annualized change in the MD Anderson symptom inventory was negatively correlated with the annualized change in the medial frontal N-acetylaspartate (Spearman correlation coefficient [rho] = −0.78, P = .01) and positively correlated with the annualized change in the posterior cingulate gyrus creatine (rho = 0.66, P = .04). Annualized changes in the Rey Osterrieth complex figure test were positively correlated with annualized changes in choline (rho = 0.83, P = .01) in the medial frontal cortex, choline (rho = 0.76, P = .04) in the left thalamus, and creatine (rho = 0.73, P = .02) in the medial frontal cortex. Our data suggest that chemotherapy may lead to the worsening of self-reported memory function, which is associated with alterations in brain metabolites.